Thin
Pre-formulated, high-purity synthetic peptide APIs supporting early-stage R&D, clinical development, and commercial scale-up across Ontario, Quebec, and British Columbia biotech clusters.
Addressing patent expiries, Health Canada's strict Module 3 requirements, and clinical manufacturing demands across Montreal, Toronto, and Vancouver.
Navigating Therapeutic Products Directorate (TPD) submissions demands complete impurity profiling, stereochemical verification, and residual peptide sequence validation down to <0.05% thresholds.
With diabetes incidence growing across Canadian provinces, generic drug developers require massive volumes of Semaglutide, Tirzepatide, and Dulaglutide APIs ahead of impending Canadian patent cliffs.
Canada’s sub-zero winters and expansive geographic logistics necessitate ultra-stable lyophilized peptide matrices accompanied by temperature-monitored IATA cold-chain packaging protocols.
Combining Solid-Phase Peptide Synthesis (SPPS) automation, inline PAT analytical monitoring, and multiton commercial scalability to guarantee cost and quality supremacy.
For long chain glucagon-like peptides, we deploy segment condensation technology to drastically minimize truncation sequences, boosting raw yield by 35% compared to standard batch SPPS.
Utilizing high-resolution UHPLC-Q-TOF-MS, tandem quadrupole MS, and validated 2D NMR spectroscopy to document purity profiles well above 99.0% with transparent optical purity validation.
With an automated central processing plant based in Hangzhou, our automated multi-ton synthesis lines eliminate single-batch discrepancies and shield Canadian clients from severe market fluctuations.
Aligning raw active substance sourcing with commercial timelines, technical regulatory packs, and commercial viability.
Complete CTD format Module 3 documentation, validation batch data, stability files under accelerated & long-term ICH conditions, and rapid Health Canada Type I/IV MF access letters.
For injectable therapeutic peptides, bacterial endotoxin limits <0.5 EU/mg and bioburden control are confirmed through validated USP/EP/ChP compendial methods.
Transparent volume pricing schemes designed to transition seamlessly from pre-clinical kilogram requirements to recurring annual multi-ton supply commitments.
Incretins, GnRH analogues, tissue regenerators, and aesthetic actives manufactured under rigorous GMP process validation.
Addressing documentation, customs clearance via CBSA, analytical verification, and logistical compliance for cross-border pharmaceutical procurement.
Connect with our technical commercial specialists for comprehensive CoAs, Master File support, and tailored multi-kilogram quotes designed specifically for Canadian pharmaceutical enterprises.
Send Inquiry Now